TY  - JOUR
AU  - Takayama, Ken-ichi
PY  - 2018
DA  - 2018/11/02
TI  - Epigenetic Regulation by Androgen Receptor in Prostate Cancer
JO  - OBM Genetics
SP  - 047
VL  - 02
IS  - 04
AB  - Prostate cancer is the most common cancer among men in the world. Androgen receptor (AR), acting as a nuclear receptor, facilitates ligand-dependent transcriptional activation in the nucleus. Androgen deprivation therapy (ADT) is used for the treatment of advanced prostate cancer because androgen and AR signaling drive prostate tumor growth and anti-apoptotic function. Resistance to ADT in most tumors develops quickly; thus, AR continues to be active in relapsed tumors called castration-resistant prostate cancer (CRPC). Therefore, it is important to investigate the transcriptional mechanisms of AR and its downstream signaling. Recent studies have shown the central role of chromatin structure and histone modifications in AR-mediated gene regulation. Furthermore, AR functions through interaction with several tissue-specific transcription factors including forkhead box protein A1 (FOXA1). Interestingly, non-coding RNAs, mainly classified as long non-coding RNAs (lncRNAs) and micro RNAs (miRNAs), modulate epigenetic status to promote AR function directly or indirectly and have central roles in prostate cancer progression. This review focuses on the involvement of AR in epigenetic regulation of the development and progression of prostate cancer.
SN  - 2577-5790
UR  - https://doi.org/10.21926/obm.genet.1804047
DO  - 10.21926/obm.genet.1804047
ID  - Takayama2018
ER  -